- Sinclair Pharma said it still expected to post modest annual earnings growth after revenue rose as expected. Sales for the year through December rose by 20% to Â£45.3m, or by 14% on a constant currency basis. "As previously guided, the group expects to deliver a modest Ebitda profit for the year as a whole," the company said. At 9:29am: [ ] Sinclair IS Pharma PLC share price was +1.95p at 23.45p Story provided by StockMarketWire.com
Global aesthetic dermatology firm Sinclair Pharma is forecast to deliver a modest profit. The London-based company saw revenue rise as expected, with sales for the year to December rising by 20% to £45.3m ($62.3m) or by 14% on a constant currency basis. In a statement, the group said it "expects to deliver a modest Ebitda profit for the year as a whole", as previously guided.